Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):185-92. doi: 10.1016/j.ijrobp.2010.01.034. Epub 2010 Apr 17.
To provide the long-term outcomes of patients treated with fractionated conformal radiotherapy (FCRT) for presumed optic nerve sheath meningiomas (ONSMs).
Between 1995 and 2002, 9 patients with a presumed ONSM were treated with FCRT at our institution. The indications for FCRT were significant visual dysfunction at presentation, progression of visual dysfunction during a period of observation, tumor growth documented by sequential imaging, or a combination of these findings. In 2 patients, FCRT was performed as adjuvant therapy, and in 7, it was the initial and primary treatment.
Of the 9 patients, 6 were women and 3 were men, with a mean age of 47 years. All 9 patients had evidence of optic nerve dysfunction in the affected eye, characterized by reduced visual acuity, a visual field defect, and a relative afferent pupillary defect. In addition, 2 patients had proptosis and 1 had diplopia. The mean follow-up period was 98 ± 31.7 months (median, 90; range, 61-151). After FCRT, the visual function improved in the 7 patients who had undergone FCRT as the primary treatment. However, 2 patients who were blind in their affected eye at FCRT remained blind. In 4 of the 7 patients with improvement, the improvement was documented within 1-3 months after FCRT. The tumor control rate was 100%. Proptosis and diplopia also regressed in 100% of patients. At 2 years after FCRT, 1 patient had developed radiation retinopathy.
The results of our study have shown that FCRT is a safe and effective treatment of ONSMs, affording satisfactory long-term tumor control, good functional outcome, and low treatment morbidity. FCRT should be considered the treatment of choice for patients with presumed ONSMs for whom the treatment has been deemed appropriate.
提供接受分割适形放疗(FCRT)治疗的疑似视神经鞘脑膜瘤(ONSM)患者的长期结果。
1995 年至 2002 年间,我院对 9 例疑似 ONSM 患者行 FCRT 治疗。行 FCRT 的适应证为:初诊时存在明显的视力障碍、观察期间视力障碍进展、连续影像学检查发现肿瘤生长,或这些表现的组合。2 例患者行 FCRT 作为辅助治疗,7 例患者行 FCRT 作为初始和主要治疗。
9 例患者中,6 例为女性,3 例为男性,平均年龄为 47 岁。9 例患者的受影响眼均有视神经功能障碍的证据,表现为视力下降、视野缺损和相对性传入性瞳孔障碍。此外,2 例患者有眼球突出,1 例有复视。平均随访时间为 98±31.7 个月(中位数 90;范围 61-151)。行 FCRT 后,7 例作为初始治疗的患者的视力功能得到改善。然而,2 例在 FCRT 时视力已盲的患者仍失明。7 例视力改善的患者中,有 4 例在 FCRT 后 1-3 个月内记录到改善。肿瘤控制率为 100%。100%的患者的眼球突出和复视也消退。FCRT 后 2 年,1 例患者发生放射性视网膜病变。
我们的研究结果表明,FCRT 是治疗 ONSM 的一种安全有效的方法,可获得满意的长期肿瘤控制、良好的功能结果和低治疗发病率。对于认为合适的疑似 ONSM 患者,应考虑将 FCRT 作为治疗选择。